Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Where you live can affect how long you survive kidney cancer. A new retrospective study found that patients with metastatic renal cell carcinoma (mRCC) who scored highest on the CDC's Social Vulnerability Index had a median overall survival of just 24.6 months, compared to 37.2 months for those with the lowest scores. The findings highlight persistent disparities in cancer care tied to socioeconomic and minority status.
Where you live — and how vulnerable your community is — may significantly shape your odds of surviving metastatic kidney cancer. A retrospective study presented at IKCS: North America 2026 found that patients with metastatic renal cell carcinoma (mRCC) in the most socially vulnerable group had markedly worse survival outcomes than those in the least vulnerable group. Researchers at Winship Cancer Institute of Emory University analyzed 291 mRCC patients treated between 2018 and 2023, using the CDC's Social Vulnerability Index (SVI) — which factors in socioeconomic status, household characteristics, minority status, and housing/transportation — to stratify patients into three groups.
The gap in outcomes was stark across both progression-free and overall survival, with the highest-vulnerability patients faring worst at every time point measured. Researchers noted that disparities tied to minority status were especially significant and called for community-focused interventions to close the gap.
By the Numbers:
Why it matters: These findings underscore that cancer outcomes aren't determined solely by biology or treatment — social determinants of health play a powerful role. For clinicians and health systems, addressing these disparities through targeted, community-level interventions could meaningfully improve survival for mRCC patients in vulnerable populations.